Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis

QIANG WANG1*, ZHENZHEN WEN2* and QIAN CAO2

1Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014;  2Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China

Received May 12, 2015; Accepted June 27, 2016

DOI: 10.3892/etm.2016.3548

Abstract. Infliximab is a promising drug with good outcomes demonstrated for diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthropathy (SpA). However, treatment with this drug may increase the risk of tuberculosis infection. The aim of the present study was to investigate infliximab-associated tuberculosis infection. Literature searches in PubMed, MEDLINE and EMBASE databases were performed. Randomized controlled trials with >95% of the patients >18 years-old were included. Meta-analysis was performed to investigate the incidence of tuberculosis infection after infliximab infusion. A total of 24 RCTs were included in the present meta-analysis. In total, 21 (0.51%) tuberculosis infections were detected among 4,111 patients administered infliximab therapy, compared with 0 (0%) among 2,229 patients assigned to the placebo group. Pooled odds ratio (OR) of developing tuberculosis infection was significantly higher with infliximab therapy than with placebo [2.86; 95% confidence interval (CI), 1.09-7.52]. The OR of tuberculosis infection was 3.93 (95% CI, 0.91-16.91) in RA, 2.46 (95% CI, 0.38-15.92) in SpA and 1.66 (95% CI, 0.26-10.57) in IBD. Rates of tuberculosis infection with infliximab therapy in RA, SpA and IBD were 0.70, 0.22 and 0.52%, respectively. Compared with placebo, infliximab therapy may increase the risk of developing tuberculosis. However, the ORs for the risk of infliximab-associated tuberculosis were not demonstrated to be significant in IBD, RA and SpA; therefore, these findings should be interpreted with caution. The risk of developing tuberculosis demonstrates the importance of the prevention and management of tuberculosis infection with infliximab therapy.

Introduction

Infliximab is a genetically constructed immunoglobulin (Ig)G1 murine-human chimeric monoclonal antibody that binds the soluble subunit and the membrane-bound precursor of tumor necrosis factor-α (TNF-α). Consequently, it helps to decrease the biological activity of TNF-α (1,2). Neutralization of TNF-α has been suggested as a therapeutic strategy for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthropathy (SpA) and various other chronic inflammatory conditions (3-5). IBD, RA, and SpA are common chronic inflammatory conditions, characterized by episodes of remission and relapse, which have a major impact on the patients' physical, emotional and social well-being. TNF-α cytokine, which is expressed by activated macrophages, has been implicated in the pathogenesis of IBD, RA and SpA (6-8). Infliximab has been widely used to treat patients who failed to respond to other anti-inflammatory agents since FDA approval was attained in 1998. The advent of infliximab has dramatically improved the quality of life and prognosis of these patients.

Multicenter randomized clinical trials (RCTs) have been conducted to evaluate the efficacy and safety of infliximab throughout the past decade. These RCTs demonstrated that infliximab is an effective therapy for the treatment of various inflammatory diseases (9-12). However, the safety of infliximab remains a major concern to physicians and patients, including its short- and long-term side effects, which have limited its clinical use. Although the side effects are uncommon, they may be serious and potentially life-threatening. The most common side effects include infection, infusion reactions, tumor and lupus-like syndrome. Miscellaneous types of infections, such as bacterial, mycobacteria, invasive fungal, viral and parasitic infections have been observed since the approval of infliximab (13).
In animal models, TNF-α has been demonstrated to have a central role in the host response against tuberculosis, including granuloma formation and the containment of disease (14,15). Notably, antibodies against TNF-α induced reactivation of tuberculosis in a mouse model of latent infection (16). The role of TNF-α in the human immune response to tuberculosis remains unclear, and the effect on the tuberculosis infection of infliximab requires clarification. Previous large retrospective reviews of infliximab-induced tuberculosis have shown that the frequency of tuberculosis following infliximab therapy was elevated, as compared with other opportunistic infections (17). In addition, the rate of reported cases of tuberculosis treated with infliximab is higher than the background rate of tuberculosis in patients with rheumatoid arthritis (18-20). However, the findings of previous RCTs that examined the association between infliximab and tuberculosis infection risk were inconsistent. The aim of present study was to analyze the findings of RCTs that investigated infliximab, with an emphasis on tuberculosis infection risk.

Materials and methods

Search strategy and study selection. To perform this review, we conducted a structured search in PubMed (ncbi.nlm.nih.gov/pubmed), MEDLINE (http://webofknowledge.com/medline) and EMBASE (http://www.embase.com) databases up to May 2014 using the following search terms: (‘inflammatory bowel disease’ or ‘Crohn's disease’ or ‘ulcerative colitis’ or ‘rheumatoid arthritis’ or ‘spondyloarthropathy’) and (‘remicade’ or ‘infliximab’ or ‘monoclonal antibody cA2’) and (‘tuberculosis’ or ‘mycobacterial infections’). References from the articles that met the eligibility criteria were also examined and evaluated, and were selected for this review if they also met the criteria. Only articles published in English were included. Titles and abstracts of articles identified by the initial search were first evaluated by investigators for appropriateness to the study question, and full papers of potential eligible studies were subsequently obtained and reviewed in detail. The present meta-analysis was designed, analyzed and reported according to the PRISMA statement (21).

Criteria for the inclusion of an article in the present meta-analysis were as follows: (i) Randomized controlled trials; (ii) >95% of the patients are aged >18 years; and (iii) compared infliximab with or without concomitant immunomodulators therapy with placebo. Furthermore, for inclusion, studies were required to be independent from other studies in order to avoid giving double weight to estimates derived from the same trial, and to have sufficient information to allow adequate estimation of the relative risk (RR)/odds ratio (OR) and 95% confidence intervals (CIs).

Studies were excluded if: (i) They were a review, lecture, comment or research that cannot be extracted with statistical data; or (ii) they included patients that were pregnant, hypersensitive to infliximab, exhibited systemic disease, or were given biological treatment previously.

Outcome assessment. The primary outcome was the occurrence of tuberculosis infection with infliximab, compared with placebo. The secondary outcome was mortality due to tuberculosis infection.

Data extraction. Two investigators individually evaluated all relevant articles identified by the literature search using pre-defined eligibility forms. Any discrepancies were resolved by discussion. The following information was obtained from each study: First author, year of publication, geographical region, disease type, sample size during the study, dosage of infliximab, duration of therapy, combination therapy (if any), number of individuals who experienced tuberculosis infection, tuberculosis manifestation, and prognosis of tuberculosis. Data were extracted as intention-to-treat analyses, wherever trial reporting facilitated this.

Quality evaluation. Jadad scoring was applied to assess the methodological quality of included trials, which judges the descriptions of randomization, double blinding, and subject withdrawal in the included trials (22). The quality scale ranges from 0 to 5 points with a low-quality report scoring ≤2 and a high-quality report scoring ≥3 (23).

Statistical analysis. Statistical heterogeneity between the studies was assessed using χ² test and F, which assumes the presence of heterogeneity at P<0.10 and/or F>50%. A fixed effects model was used when the heterogeneity test demonstrated a P-value of >0.10 and a F of <50%; otherwise, a random-effects model was used. Subgroup analyses were performed according to disease type, sample size, study quality, duration of therapy, whether patients in both infliximab and placebo arms were exposed to immunosuppressants and whether patients enrolled in infliximab and placebo arms were screened for tuberculosis. We compared individual ORs between these analyses using the Cochran Q statistic tool.

Funnel plot graph, and Begg and Egger tests were performed to evaluate publication bias. All analyses were conducted using the Revman 5.0 (Nordic Cochrane Centre, Copenhagen, Denmark) and Stata software (11.0; StataCorp LP, College Station, TX, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Literature search and characteristics of the included studies. The present search strategy identified 6,892 articles, 6,553 of which were excluded after the title and abstract were reviewed. For the remaining 339 articles, 316 articles were excluded due to duplication (n=54), not being an RCTs (n=127), a lack of placebo (n=67), no outcome of interest (n=49), and no data on tuberculosis (n=19). Finally, 23 articles were included in the present meta-analysis, reporting on 24 respective RCTs. Of these, 8 studies studied infliximab-associated tuberculosis incidence in IBD (24-32), one of which reported two separate trials (29), 7 trials studied infliximab-associated tuberculosis incidence rates in RA (33-39), and 8 trials studied infliximab-associated tuberculosis incidence in SpA (40-47). A flow diagram of the selection process for the inclusion of studies in the present meta-analysis is shown in Fig. 1. Duration of follow-up ranged between 12 and 54 weeks. The characteristics of the 24 trials are presented in...
meta-analysis of tuberculosis infection with infliximab therapy vs. placebo in each subgroup. Subgroup analyses were performed (Table IV). The OR of tuberculosis infection with infliximab therapy was elevated in trials with ≥50 weeks of treatment (3.00; 95% CI, 0.97-9.29), as compared with those with a duration of <50 weeks (2.46; 95% CI, 0.38-15.92); however, there was no statistically significance (Cochran Q=0.03; P=0.86). Furthermore, the OR was also increased in the larger sample studies (2.94; 95% CI, 0.87-9.94), as compared with the smaller sample studies (2.71; 95% CI, 0.55-13.26); however, again there was no significant differences detected (Cochran Q=0.01; P=0.93). There were also no significant differences in the OR of tuberculosis infection with infliximab therapy accompanied with or without immunosuppressor (2.96; 95% CI, 0.94-9.29; and 2.59; 95% CI, 0.42-15.92; respectively, Cochran Q=0.02, P=0.90). When screening for tuberculosis prior to the examination of therapy according to the study design, the OR was also increased in trials that screened for tuberculosis (3.10; 95% CI, 1.04-9.21), as compared with those without screening (2.09; 95% CI, 0.26-17.13) (Cochran Q=0.11, P=0.74). Finally, risk of bias was judged in the RCTs (Fig. 3), the OR was elevated in trials with high or unclear risk (3.14; 95% CI, 0.93-10.54), as compared with those at low risk (2.35; 95% CI, 0.47-11.77); however, there was also no significant differences detected (Cochran Q=0.08; P=0.78). The results showed that subgroup differences did not increase the risk of tuberculosis infection with infliximab therapy compared with placebo.

Publication bias. Funnel plot analysis was performed, as demonstrated in Fig. 4. Funnel plot asymmetry was detected in the present meta-analysis (Egger test, P=0.002 and Begg test, P=0.004). These results provide some evidence of publication bias in the present study.

Discussion

TNF-α is required for granuloma formation and maintenance, and has an important role in host defense against diseases caused by intracellular pathogens, such as Mycobacterium tuberculosis, Histoplasma capsulatum and Listeria monocytogenes (48-50). The increased clinical use of TNF-α antagonists has markedly improved the management of immunomediated diseases; however, it may have led to an increase in the incidence of infections with intracellular agents. To the best of our knowledge, the present meta-analysis was the first to evaluate the potential risk of tuberculosis infection with infliximab therapy in the management of RA, SpA and IBD, by collating all obtainable data from 24 individual RCTs. The present meta-analysis demonstrated that the OR of tuberculosis infection with infliximab therapy was 2.86-fold greater than when using the placebo. However, the ORs in all three disease subgroups were not demonstrated to be statistically significant.

The role of TNF-α in the human immune response to M. tuberculosis is yet to be fully elucidated. An in vitro study has proposed that TNF-α has a significant role in the regulation of granuloma formation, which limits microbial growth (51). TNF-α, which is a pleiotropic cytokine produced by infected and activated macrophages/proinflammatory T cells, enhances
Table I. RCTs evaluating the incidence of infliximab-associated tuberculosis in patients with RA, SpA and IBD.

| Author, year | Country | Study design | Disease | Treatment (number of patients) | Duration (wks) | Ref. |
|-------------|---------|--------------|---------|--------------------------------|----------------|-----|
| Maini et al, 1998 | Netherlands, Germany, Austria, UK | MC, DB, PC, phase 3 RCT; MTX allowed | Active RA | Grp 1: Placebo plus MTX (n=14)  
Grp 2: Placebo plus 1 mg/kg infliximab q4wks (n=14)  
Grp 3: MTX plus 1 mg/kg infliximab q4wks (n=15)  
Grp 4: Placebo plus 3 mg/kg infliximab q4wks (n=15)  
Grp 5: MTX plus 3 mg/kg infliximab q4wks (n=14)  
Grp 6: Placebo plus 10 mg/kg infliximab q4wks (n=14)  
Grp 7: MTX plus 10 mg/kg infliximab q4wks (n=15) | 26 | (33) |
| Lipsky et al, 2000 | USA, Netherlands, Germany, Austria, UK | MC, DB, PC, phase 3 RCT (ATTRACT); corticosteroids and NSAIDs allowed | Active RA | Grp 1: MTX plus placebo at wks 0, 2, 6 and q4wks (n=88)  
Grp 2: MTX plus infliximab 3 mg/kg at wks 0, 2, 6 and every 8 wk (n=86)  
Grp 3: MTX plus infliximab 3 mg/kg at wks 0, 2, 6 and every 4 wk (n=86)  
Grp 4: MTX plus infliximab 10 mg/kg at wks 0, 2, 6 and every 8 wk (n=87)  
Grp 5: MTX plus infliximab 10 mg/kg at wks 0, 2, 6 and every 4 wk (n=81) | 54/104 | (34) |
| St Clair et al, 2004 | North America, and Europe | MC, PC, phase 3 RCT (ASPIRE); corticosteroids and NSAIDs allowed | Early RA (≤3 years) | All patients: MTX 7.5 mg/week, which increased to 15 mg/week by wk 4 and 20 mg/week by wk 8 (n=1,004)  
Grp 1: Placebo at wks 0, 2, 6 and q8wks through wk 46 (n=282)  
Grp 2: Infliximab 3 mg/kg at wks 0, 2, 6 and q8wks through wk 46 (n=359)  
Grp 3: Infliximab 6 mg/kg at wks 0, 2, 6 and q8wks through wk 46 (n=363) | 54 | (35) |
| Quinn et al, 2005 | UK | DB, PC RCT; MTX allowed | Early poor prognosis RA | Grp 1: Placebo plus MTX (n=10)  
Grp 2: 3 mg/kg infliximab at wks 0, 2, 6 and q8wks plus MTX (n=10) | 48 | (36) |
| Westhovens et al, 2006 | Belgium, US, Netherlands | MC, DB, PC, phase 3 RCT (START); AZA, 6-MP MTX, DMARDs and corticosteroids allowed | Active RA | Grp 1: Placebo at wks 0, 2, 6 and 14, and infliximab 3 mg/kg at wks 22, 26, and 30, and q8wks through wk 46 (n=363)  
Grp 2: Infliximab 3 mg/kg at wks 0, 2, 6, 14 and at least 3 mg/kg q8wks through wk 46 (n=360)  
Grp 3: Infliximab 10 mg/kg at 0, 2, 6, 14 and q8wks through wk 46 (n=361)  
Grp 4: Placebo plus MTX (n=47)  
Grp 2: 3 mg/kg infliximab at wks 0, 2, 6 plus MTX (n=49)  
Grp 3: 10 mg/kg infliximab at wks 0, 2 and 6 wk plus MTX (n=51)  
Most of Grp 1, 2 and 3: 3 mg/kg infliximab q8wks plus MTX thereafter | 54 | (37) |
| Abe et al, 2006 | Japan | MC, DB, PC RCT; corticosteroids and NSAIDs allowed | RA | Grp 1: Placebo plus MTX (n=47)  
Grp 2: 3 mg/kg infliximab at wks 0, 2, 6 plus MTX (n=49)  
Grp 3: 10 mg/kg infliximab at wks 0, 2 and 6 wk plus MTX (n=51)  
Most of Grp 1, 2 and 3: 3 mg/kg infliximab q8wks plus MTX thereafter | 36 | (38) |
| Schiff et al, 2008 | Brazil, America, Argentina, France, Mexico | DB, PC phase 3 RCT (ATTRACT) | RA | Grp 1: Placebo plus MTX (n=110)  
Grp 2: 3 mg/kg infliximab plus MTX at wks 0, 2, 6, 14, every 8 wk (n=165) | 52 | (39) |
## B. Spondyloarthropathy

| Author, year | Country | Study design | Disease | Treatment (number of patients) | Duration (wks) | Ref. |
|--------------|---------|--------------|---------|--------------------------------|----------------|-----|
| Braun et al, 2002 | Germany | MC, DB, PC, phase 2 RCT; NSAIDs allowed | Severe AS | Grp 1: Placebo at wks 0, 2, 6 (n=35) Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6 (n=35) | 12 | (40) |
| Van der Heijde et al, 2005 | Europe, US, Canada | MC, DB, PC, phase 3 RCT (ASSERT); NSAIDs allowed | Active AS | Grp 1: Placebo at wks 0, 2, 6, 12 and 18 (n=78) Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6, 12 and 18 (n=201) | 24 | (41) |
| Marzo-Ortega et al, 2005 | UK | DB, PC, phase 2 RCT; NSAIDS and corticosteroids allowed | Active AS | Grp 1: Infliximab 5 mg/kg at wks 0, 2, 6 14, 22 + MTX 7.5 mg/week (n=28) Grp 2: Placebo+MTX 7.5 mg/sem (n=14) | 30 | (42) |
| Inman et al, 2010 | Canada | MC, DB, PC, phase 3b RCT; NSAIDS and corticosteroids allowed | Active AS | Grp 1: Placebo (n=37) Grp 2: Infliximab 3 mg/kg at wks 0, 2, 6 and q8wks through wk 52 (n=39) All patients: Infliximab 5 mg/kg at wks 22 or 38 if BASDAI>3 and a relative decrease of <50% in BASDAI | 52 | (43) |
| Van den Bosch et al, 2002 | Belgium | DB, PC, phase 2 RCT; corticosteroids and NSAIDs allowed | Active SpA | Grp 1: Placebo at wks 0, 2, 6 (n=20) Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6 (n=20) | 12 | (44) |
| Antoni et al, 2002 | Europe, US, Canada | MC, DB, PC, phase 3 RCT (IMPACT); one of MDARDs allowed | Active SpA | Grp 1: Placebo at wks 0, 2, 6, and 14 (n=52) then infliximab 5 mg/kg at wks 16, 18, 22, 30,38 and 46 (n=50) Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6, and 14 (n=52), placebo at wks 16, 18 and infliximab 5 mg/kg at wks 22, 30, 38 and 46 (n=49) | 50 | (45) |
| Kavanaugh et al, 2005 | Europe, US, Canada | MC, DB, PC, phase 3 RCT (IMPACT II); MTX and corticosteroids allowed | Active SpA | Grp 1: Placebo at wks 0, 2, 6, and q8wks through wk 22 (n=100) Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6, and q8wks to wk 22 (n=100) | 24 | (46) |
| Sieper et al, 2007 | Austria, Europe, South Korea | MC, DB, PC Phase 3b RCT (INFAST) | MTS active axial SpA | Grp 1: Placebo+ naproxen 1000 mg/d at wks 0, 2, 6, 12, 18, 24 wks (n=52) Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6, 12, 18, 24 wks (n=105) | 24 | (47) |

## C. Inflammatory bowel disease

| Author, year | Country | Study design | Disease | Treatment (number of patients) | Duration (wks) | Ref. |
|--------------|---------|--------------|---------|--------------------------------|----------------|-----|
| Present et al, 1999 | North America and Europe | MC, DB, PC phase 3 RCT | Fistulizing CD | Grp 1: Infliximab 10 mg/kg at wks 0, 2, 6 (n=32) Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6 (n=31) Grp 3: Placebo at wks 0, 2, 6 (n=31) | 52 | (25) |
| Author, year | Country | Study design | Disease | Treatment (number of patients) | Duration (wks) | Ref. |
|-------------|---------|--------------|---------|-------------------------------|---------------|-----|
| Sands et al., 2001 | US | MC, DB, PC phase 2, RCT | Active UC | Grp 1: Single dose of placebo (n=3) | 12 | (26) |
| | | | | Grp 2: Single dose of infliximab 5 mg/kg (n=3) | | |
| | | | | Grp 3: Single dose of infliximab 10 mg/kg (n=3) | | |
| | | | | Grp 4: Single dose of infliximab 20 mg/kg (n=2) | | |
| Hanauer et al., 2002 | North America, Europe, Israel | MC, DB, PC, phase 3 RCT (ACCENT I); AZA 6-MP, MTX and corticosteroids allowed | MTS CD | All patients: Infliximab 5 mg/kg at wk 0 (n=573) | 54 | (27) |
| | | | | Grp 1: Placebo at wks 2, 6 and q8wks to wk 46 (n=188) | | |
| | | | | Grp 2: Infliximab 5 mg/kg at wks 2, 6 and q8wks to wk 46 (n=192) | | |
| | | | | Grp 3: Infliximab 5 mg/kg at wks 2 and 6 and 10 mg/kg q8wks to wk 46 (n=193) | | |
| Sands et al., 2004 | North America, Europe, Israel | MC, DB, PC, phase 3 RCT (ACCENT II); AZA, 6-MP, MTX and corticosteroids allowed | Fistulizing CD | All patients: Infliximab 5mg/kg at wks 0, 2, 6 (n=306) | 54 | (28) |
| | | | | Grp 1: Placebo at wk 14 and q8wks through wk 46 (n=144) | | |
| | | | | Grp 2: Infliximab 5 mg/kg at wk14 and q8wks to wk 46 (n=138) | | |
| Rutgeerts et al., 2005 | Belgium, Canada, Israel, America, France | MC, DB, PC, phase 3 RCT (ACT I); AZA, 6-MP and corticosteroids allowed | Active UC | Grp 1: Placebo at wks 0, 2, 6 and q8wks to wk 46 (n=121) | 54 | (29) |
| | | | | Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6 and q8wks to wk 46 (n=121) | | |
| | | | | Grp 3: Infliximab 10 mg/kg at wks 0, 2, 6 and q8wks to wk 46 (n=122) | | |
| Rutgeerts et al., 2005 | Belgium, Canada, Israel, America, France | MC, DB, PC, phase 3 RCT (ACT II); AZA, 6-MP and corticosteroids allowed | Active UC | Grp 1: Placebo at wks 0, 2, 6 and q8wks through wk 22 (n=123) | 54 | (29) |
| | | | | Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6 and q8wks to wk 22 (n=121) | | |
| | | | | Grp 3: Infliximab 10 mg/kg at wks 0, 2, 6 and 10 mg/kg q8wks to wk 22 (n=120) | | |
| Lemann et al., 2006 | France | MC, DB, PC, phase 2 RCT; AZA and 6-MP allowed | Luminal steroid-dependent CD | Grp 1: Placebo (n=58) | 52 | (30) |
| | | | | Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6 (n=57) | | |
| Colombel et al., 2010 | Netherlands, Belgium, France | MC, DB, phase 3 RCT (SONIC); AZA, 6-MP and corticosteroids allowed | MTS CD | Grp 1: AZA 2.5 mg/kg capsules/placebo infusion (n=161) | 50 | (31) |
| | | | | Grp 2: Placebo capsules/infliximab 5 mg/kg infusions (n=63) | | |
| | | | | Grp 3: AZA 2.5 mg/kg capsules/infliximab 5 mg/kg infusions (n=179) | | |
| | | | | Capsules (daily)/infusions (wks 0, 2, 6, q8wks to wk 22) | | |
| Ochsenkuhn et al., 2004 | Germany | SC, OL, PC phase 2 RCT; AZA and 6-MP allowed | Active UC | Grp 1: Prednisolone 1.5 mg/kg qd for 2 wks, followed by a tapering regimen with a weekly reduction of 5 mg (n=7) | 14 | (32) |
| | | | | Grp 2: Infliximab 5 mg/kg at wks 0, 2, 6 (n=6) | | |

RCT, randomized controlled trial; RA, rheumatoid arthritis; SpA, spondyloarthropathy; IBD, inflammatory bowel disease; wks, weeks; Grp, group; q8wks, every 8 weeks; MC, multicenter; DB, double-blind; PC, placebo-controlled; AS, ankylosing spondylitis; DMARDS, disease-modifying antirheumatic drugs; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; AZA, azathioprine; 6-MP, 6-mercaptopurine; CD, Crohn's disease; UC, ulcerative colitis; OL, open label; SC, single center; MTS, moderate-to-severe; MT&W, modified Truelove and Witts.
Table II. Characteristics of the included randomized clinical trials.

| Author, year | Patients treated with infliximab | Patients that developed TB with infliximab | Patients treated with placebo | Patients that developed TB with placebo | TB manifestation | Prognosis | Screened | Ref. |
|--------------|----------------------------------|-------------------------------------------|-------------------------------|------------------------------------------|-----------------|-----------|----------|------|
| **Inflammatory bowel disease** | | | | | | | | |
| Present et al, 1999 | 63 | 0 | 31 | 0 | NS | NS | NS (25) | |
| Sands et al, 2001 | 8 | 0 | 3 | 0 | NS | NS | NS (26) | |
| Hanauer et al, 2002 | 385 | 1 | 188 | 0 | NS | Recovered | PPD and CXR (27) | |
| Sands et al, 2004 | 6 | 0 | 7 | 0 | NS | NS | NS (28) | |
| Rutgeerts et al, 2005 | 241 | 1 | 123 | 0 | NS | NS | PPD and CXR (29) | |
| Rutgeerts et al, 2005 | 243 | 0 | 212 | 0 | NS | NS | PPD and CXR (29) | |
| Lemann et al, 2006 | 57 | 0 | 58 | 0 | NS | Recovered | PPD and CXR (30) | |
| Colombel et al, 2010 | 242 | 1 | 161 | 0 | NS | NS | NS (31) | |
| Ochsenkuhn et al, 2004 | 138 | 0 | 144 | 0 | NS | NS | NS (32) | |
| **Rheumatoid arthritis** | | | | | | | | |
| Maini et al, 1998 | 87 | 0 | 14 | 0 | NS | NS | No (33) | |
| Lipsky et al, 2000 | 340 | 1 | 88 | 0 | Disseminated TB | DNS (resistant TB) | No (34) | |
| St Clair et al, 2004 | 722 | 4 (US, 1; Europe, 3) | 282 | 0 | 4 Pulmonary | Recovered | No (35) | |
| Quinn et al, 2005 | 10 | 0 | 10 | 0 | NS | NS | CXR (36) | |
| Westovens et al, 2006 | 724 | 8 | 363 | 0 | 2 Pulmonary, 5 extrapulmonary (not disseminated) | 1 DNS | CXR (37) | |
| Abe et al, 2006 | 100 | 0 | 47 | 0 | NS | NS | CXR (38) | |
| Schif et al, 2008 | 165 | 2 | 110 | 0 | 1 Pulmonary, 1 extrapulmonary | Recovered | Yes (39) | |
| **Spondyloarthritis** | | | | | | | | |
| Braun et al, 2002 | 35 | 1 | 35 | 0 | Disseminated TB | Recovered | CXR, not PPD (40) | |
| van der Heijde et al, 2005 | 201 | 0 | 78 | 0 | NS | NS | CXR or PPD (41) | |
| Marzo-Ortega et al, 2005 | 28 | 0 | 14 | 0 | NS | NS | Yes (42) | |
| Inman et al, 2010 | 39 | 0 | 37 | 0 | NS | NS | NS (43) | |
| Van den Bosch et al, 2002 | 20 | 1 | 20 | 0 | Disseminated TB | Recovered | Yes (44) | |
| Antoni et al, 2005 | 100 | 0 | 100 | 0 | NS | NS | NS (45) | |
| Kavanaugh et al, 2007 | 52 | 0 | 52 | 0 | NS | NS | CXR, PPD (46) | |
| Sieper et al, 2014 | 105 | 1 | 52 | 0 | NS | Recovered | CXR, PPD (47) | |

TB, tuberculosis; PPD, purified protein derivative; CXR, chest X-ray; NS, not stated; DNS, did not survive.
macrophage activation, chemokine production by macrophages, and immune cell recruitment during tuberculosis infection (51). Anti-TNF-α monoclonal antibody administration may subsequently increase the risk of the dissolution of intact granulomas, the production of viable mycobacteria, and disease reactivation. This may clarify the increased likelihood of tuberculosis that was observed in patients receiving infliximab therapy.

In the present meta-analysis, 21 cases of tuberculosis, including 15 patients with RA, 3 patients with SpA and 3 patients with IBD, were evaluated. There were some limitations to the present study, even though the probability in each disease subgroup was not statistically significant. Firstly, as a consequence of latent tuberculosis infection (LTBI) screening, a relatively low number of cases of TB activation were recorded in clinical trials of infliximab in IBD, RA and

Table III. Rates of tuberculosis infection following infliximab therapy versus placebo in patients with RA, IBD and SpA.

| Disease     | Number of trials | Total number of infliximab patients | Number of infliximab patients infected with tuberculosis (%) | Total number of placebo patients | Number of placebo patients infected with tuberculosis (%) |
|-------------|------------------|--------------------------------------|---------------------------------------------------------------|---------------------------------|----------------------------------------------------------|
| RA          | 7                | 2,148                                | 15 (0.70)                                                     | 914                             | 0 (0)                                                    |
| IBD         | 8                | 580                                  | 3 (0.52)                                                      | 388                             | 0 (0)                                                    |
| SpA         | 9                | 1,383                                | 3 (0.22)                                                      | 927                             | 0 (0)                                                    |
| Total       | 24               | 4,111                                | 21 (0.51)                                                     | 2,229                           | 0 (0)                                                    |

RA, rheumatoid arthritis; IBD, inflammatory bowel disease; SpA, spondyloarthropathy.
Table IV. Subgroup analyses of the odds ratio of TB infection with infliximab therapy vs. placebo in IBD, RA and SpA.

| Variable                        | Number of trials | Number of infliximab patients | Number of placebo patients | OR of TB infection | 95% CI       | F value (%) |
|---------------------------------|------------------|-------------------------------|---------------------------|-------------------|-------------|-------------|
| All trials                      | 24               | 4,111                         | 2,229                     | 2.86              | 1.09-7.52   | 0           |
| Disease                         |                  |                               |                           |                   |             |             |
| RA                              | 7                | 2,148                         | 914                       | 3.93              | 0.91-16.91  | 0           |
| SpA                             | 8                | 580                           | 388                       | 2.46              | 0.38-15.92  | 0           |
| IBD                             | 9                | 1,383                         | 927                       | 1.66              | 0.26-10.57  | 0           |
| Duration of therapy             |                  |                               |                           |                   |             |             |
| ≥50 weeks                       | 13               | 3,327                         | 1,760                     | 3.00              | 0.97-9.29   | 0           |
| <50 weeks                       | 11               | 784                           | 469                       | 2.46              | 0.38-15.92  | 0           |
| Immunosuppressor use            |                  |                               |                           |                   |             |             |
| Yes                             | 17               | 3,390                         | 1,771                     | 2.96              | 0.94-9.29   | 0           |
| No                              | 7                | 721                           | 458                       | 2.59              | 0.42-15.92  | 0           |
| Screened for TB                 |                  |                               |                           |                   |             |             |
| Yes                             | 16               | 2,556                         | 1,471                     | 3.10              | 1.04-9.21   | 0           |
| No                              | 5                | 1,149                         | 384                       | 2.09              | 0.26-17.13  | 0           |
| Sample size^a                   |                  |                               |                           |                   |             |             |
| Large                           | 8                | 3,098                         | 1,495                     | 2.94              | 0.87-9.94   | 0           |
| Small                           | 16               | 1,013                         | 734                       | 2.71              | 0.55-13.26  | 0           |
| Risk of bias                    |                  |                               |                           |                   |             |             |
| Low risk                        | 7                | 896                           | 579                       | 2.35              | 0.47-11.77  | 0           |
| High or unclear                 | 17               | 3,215                         | 1,650                     | 3.14              | 0.93-10.54  | 0           |

^aLarge samples sizes were ≥200 participants, whereas small sample sizes were <200 participants. TB, tuberculosis; RA, rheumatoid arthritis; IBD, inflammatory bowel disease; SpA, spondyloarthropathy; OR, odds ratio; CI, confidence interval.

Figure 3. Risk of bias in 24 randomized controlled trials of tuberculosis infection with infliximab therapy.
ese findings suggest that the tuberculosis incidence rate (35,38,39). The incidence rate of anti-TNF-α for latent tuberculosis is essential prior to the administration of infliximab therapy without or with immunosuppressors. The screening for LTBI may constitute adjunctive risk factors for tuberculosis activation. Indeed, patients with SpA and IBD predominantly have limited background of immunosuppressive therapies when compared with sufferers of RA. However, not all trials included in the present study constrained the immunosuppressive therapies prior to enrollment, which may have impacted the precision of assessing the risk of infliximab therapy without or with immunosuppressors. The screening procedure for LTBI was reported in 14 trials, whereas it was not documented in the others. Conversely, despite the elevated risk that was demonstrated in the trials after the introduction of procedures to identify LTBI, screening procedures for LTBI prior to treatment are still required due to the limited sample size, relatively low incidence of tuberculosis infection and publication bias. For that reason, screening and management for latent tuberculosis is essential prior to the administration of anti-TNF-α treatments.

It has been demonstrated that infliximab infusion raises the tuberculosis incidence rate (35,38,39). The incidence rate of tuberculosis within this critique may be an underestimation, as the majority of the data that was analyzed originated from Western countries, whereas tuberculosis infection has a higher prevalence in developing countries. As is the situation in China, with the evolution of diagnostic techniques and medical treatment, RA, SpA and IBD incidence increased due to an increase in diagnosis. Despite the cost of infliximab, some patients are able to afford the cost and they are now at an increased risk for tuberculosis infection with a high latent infection rate among the population. It may be interesting to undertake multi-center clinical trials in East Asia in order to avoid inclusion bias.

By comparison, a significant proportion of extra-pulmonary and disseminated forms of tuberculosis were recognized, regardless of the preceding latent tuberculosis screening and treatment (38,39). The frame from the initial infusion to the incidence of tuberculosis varies and no obvious dose dependent effect was observed. These findings suggest that merely screening for TB and treating it prior to infliximab is not sufficient. Additional follow-up is required in order to carefully assess the potential of extra-pulmonary tuberculosis occurring at any dosage, months or years after infusion. The present meta-analysis established that infliximab therapy induced tuberculosis. This indicated that the overall likelihood of TB infection in patients receiving infliximab infusion is sufficient to justify the overall screening, prophylaxis treatment, and close observation of this potentially fatal side effect. Therefore, we consider a PPD test or tuberculin skin test and chest X-ray to be essential prior to treatment, particularly in developing countries.

The present research exhibited numerous positive aspects. Firstly, demanding and conventional methodologies were applied to conduct the present meta-analysis, including the reporting of our search strategy, inclusion criteria, and data extraction process. Moreover, data extraction was conducted by two independent reviewers. Secondly, all trials enrolled in the meta-analysis were high quality RCTs. Finally, no significant heterogeneity was detected between the studies when data were pooled to estimate the OR of tuberculosis infection with infliximab therapy vs. placebo.

The present meta-analysis has several limitations, as a result of the qualities of the published literature that is readily available for analysis. Firstly, only seven of the RCTs were at a low risk of bias, and the quantity of subjects incorporated into the present meta-analysis was limited. Secondly, with the exception of one RCT, all included trials were from developed countries with low tuberculosis incidence rates, and studies from developing countries with a high incidence of tuberculosis were not available, which resulted in a publication bias. Finally, other concerns regarding potential biases remain. In particular, the included trials did not provide any information regarding host-related risk factors, including ethnicity, malnutrition, drug abuse, comorbidity, and contact with infected persons.

In conclusion, the present meta-analysis of 24 RCTs, comprising details from >6,340 patients with RA, SpA and IBD, demonstrated that the OR of tuberculosis infection was markedly increased with infliximab therapy, as compared with placebo therapy. The overall rates of tuberculosis infection were low (0.51%).
References

1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al: Construction and initial characterization of a mouse-hamster chimeric anti-TNF antibody, Mol Immunol 30: 1443-1453, 1993.

2. Scallon BJ, Moore MA, Trinh H, Knight DM and Ghireyb J: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombiant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251-259, 1995.

3. Van Deventer SJ: Tumour necrosis factor and Crohn's disease. Gut 40: 443-448, 1997.

4. Feldmann M, Brennan FM and Maini RN: Rheumatoid arthritis. Cell 85: 307-310, 1996.

5. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M and Dougados M: Efficiency of tumour necrosis factor factor blockers in reducing uveitis flares in patients with spondyloarthritis: A retrospective study. Ann Rheum Dis 65: 1631-1634, 2006.

6. Murch SH, Braegger CP, Walker-Smith JA and MacDonald TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709, 1993.

7. Husby G and Williams RC Jr: Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1: 363-371, 1988.

8. Tse SM, Burgos-Vargas R and Laxer RM: Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthropathy. Arthritis Rheum 52: 2103-2108, 2005.

9. Aaltoinen KJ, Virkki LM, Malmivaara A, Kottinen YT, Nordström DC and Blom M: Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7: e30275, 2012.

10. Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF and Pontoraro R: A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 28: 1355-1373, 2009.

11. Wiens A, Venson R, Correr CJ, Otuki MF and Pontoraro R: Meta-analysis of the efficacy and safety of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30: 339-353, 2010.

12. Sigal AG, Periyasamy SK, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S and Wajee AE: Systematic review with network meta-analysis: The efficacy of anti-tumor necrosis factor alpha-inhibitors for the treatment of ulcerative colitis. Aliment Pharmacol Ther 39: 660-671, 2014.

13. Scheinfeld N: A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 15: 280-294, 2004.

14. Flynn JL, Goldstein MM, Chan J, Tiefbold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW and Bloom BR: Tumor necrosis factor alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561-572, 1995.

15. Kindler V, Sappino AP, Grau GE, Piguet PF and Vassalli P: The inducible form of the ECNO tumour necrosis factor is a disseminated virus. Cell 85: 307-310, 1996.

16. Moghaddam M, Scallon BJ, Lin J, Chen J, Byrd BC, Reilly LM, Wang J, Mahaffey ME, Liepnieks JJ, Herzenberg LA, et al; ACCENT I Study Group: Maintenance infliximab for fistulizing Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology 130: 1054-1061, 2006.

17. Colombo JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussaud DL, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395, 2010.

18. Ochsenuhn T, Sackmann M and Göke B: Infliximab for acute, not steroid-refractory ulcerative colitis: A randomized pilot study. Eur J Gastroenterol Hepatol 16: 1167-1171, 2004.

19. Mair A, Van der Heijden DM, St Clair EW, Walsh DE, Breedveld FC, Kalden JR, Smolen JS, Davis D, Maini RN, et al; EULAR Spondyloarthropathy Task Force: EULAR recommendations for the management of ankylosing spondylitis and spondyloarthritis in clinical practice. Ann Rheum Dis 69: 191-201, 2010.

20. Wallis RS, Broder MS, Wong JY, Hanse ME and Beenhouwer DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1265-1269, 2004.

21. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, et al: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52: 1986-1992, 2005.

22. Vedder D, Libraty D, Tetzel AF and Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097, 2009.

23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gough DJ and MacLennan G: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12, 1996.

24. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P and Klassen TP: Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613, 1998.

25. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF and Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease Maintenance Study Group. N Engl J Med 335: 1261-1265, 1996.

26. Targan SR, Hanauer SB, Mayer L, Present DH, Braakman T, DeWoody KL, et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405, 1999.

27. Sands BE, Treemaine WJ, Sandborn BW, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR and Podolsky DK: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 7: 83-88, 2001.

28. Sandborn WJ, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombo JF, Rachmilewitz D, Wolc DF, Olson A, Bao W, et al; ACCENT I Study Group: Maintenance infliximab for Crohn's disease: The ACCENT I randomized trial. Lancet 359: 1541-1549, 2002.

29. Lee A, Harnett HM, Bosworth JK, Francis J, Kornfeld M, Lee J, et al: Infliximab for the treatment of Crohn's disease. N Engl J Med 350: 876-885, 2004.

30. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476, 2005.

31. Lemmann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, et al: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology 130: 1054-1061, 2006.

32. Colombo JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussaud DL, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395, 2010.
36. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S and Emery P: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 27-35, 2005.

37. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P and Rahman MU; START Study Group: The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. Arthritis Rheum 54: 1075-1086, 2006.

38. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y and Nagaya I: A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33: 37-44, 2006.

39. Schiff M, Keiserman M, Coddin C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, et al: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67: 1096-1103, 2008.

40. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Grommica-Ihle E, Kellner H, Krause A, Schneider M, et al: Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359: 1187-1193, 2002.

41. van der Heijde D, Dijkmans B, Geusens P, Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, et al: Efficacy and safety of infliximab plus naproxen vs. naproxen alone in patients with early, active axial spondyloarthritis: Results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73: 101-107, 2014.

42. Zhou P, Miller G and Seder RA: Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol 160: 389-905, 1998.

43. Roach DR, Bean AG, Demangel C, France MP, Briscoe H and Britton WJ: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620-4627, 2002.

44. Zumla A, George A, Sharma V, Herbert N and Baroness Masham of Ilton: WHO's 2013 global report on tuberculosis: Successes, threats, and opportunities. Lancet 382: 1765-1767, 2013.